GlassScriptPhysician profile
Aazib Khan
NPI 1861811424
$17,392.15
in general payments reported to CMS, 2019-2025
32 companies · $3,847 in 2025
The $3,847 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $349 · 2021: $28.16 · 2022: $2,076 · 2023: $5,702 · 2024: $4,952 · 2025: $3,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,322 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $668 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,322.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $667.89 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5,038.92 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $2,603.13 | 2021-2025 | Watchman Flx, Watchman Access System, Baylis Medical Company Radiofrequency Puncture Generator |
| Abbott Laboratories | $2,243.17 | 2020-2025 | Aveir, Gallant, Cardiomems |
| Edwards Lifesciences Corporation | $2,156.53 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $537.72 | 2020-2025 | Farxiga, Andexxa |
| Merck Sharp & Dohme LLC | $478.08 | 2022-2025 | Verquvo, Capvaxive, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.75 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $440.98 | 2022-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $370.44 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $359.15 | 2022-2025 | Opsumit, Uptravi |
| Abiomed | $345.06 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $319.56 | 2022-2024 | Xarelto |
| Pfizer INC. | $296.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $249.97 | 2019 | |
| Amgen INC. | $235.66 | 2019-2025 | Repatha, Repatha |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $190.32 | 2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $180.98 | 2020-2024 | Onpattro, Amvuttra |
| Shockwave Medical, INC | $133.16 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $119.07 | 2025 | |
| Medtronic, INC. | $101.73 | 2024 | Attain Command + Surevalve |
| Kiniksa Pharmaceuticals International, Plc | $99.98 | 2024 | Arcalyst |
| Heartflow, INC. | $74.05 | 2022-2024 | Ffrct |
| Kestra Medical Technology Services, INC. | $67.34 | 2022-2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $57.46 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $48.11 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $44.39 | 2023-2024 | Inpefa |
| United Therapeutics Corporation | $42.25 | 2019 | |
| Esperion Therapeutics, INC. | $22.78 | 2023 | Nexletol |
| Medtronic Vascular, INC. | $21.57 | 2019 | |
| Terumo Medical Corporation | $20.83 | 2022 | |
| Novo Nordisk INC | $19.04 | 2022 | |
| Cordis US Corp. | $17.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aazib Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.